MetaBiom
Microbiome & Chronic Diseases

Evidence Based Medicine
Sign in

Atherosclerosis {40000106}

Record Keys


Definition:
Atherosclerosis
Class:[  ]

Details


Other Terms:[  ]
Initialisation date:
2020-09-06

Links


Meta Information


ICD:[  ]
Category:
Cardiovascular, Angiology, DietNutrition
MedDra ID:
10003210
MedDra Level:
pt

Notes


[  ]

Shared Notes


  • [1.6
    - Distinct members of the order Burkholderiales were present at high levels in all atherosclerotic plaques obtained from patients with atherosclerosis with the genus Curvibacter being predominant in all plaque samples. Moreover, unclassified Burkholderiales as well as members of the genera Propionibacterium and Ralstonia were typically the most significant taxa for all atherosclerotic plaques.
  • [1.7
    - Human blood platelets are a critical contributor to the hemostatic process and a crucial role in developing atherosclerosis and, finally, contribute to cardiac events.
    - Gut microbiota and their metabolites play an important role in systemic inflammation and modulate various CVD risk factors.
  • [1.8
    - Aortic atherosclerotic lesions were significantly reduced after F. nucleatum infection suggesting a potential protective function for this member of the oral microbiota.
  • [1.9
    -Clostridia (sensu stricto), bifidobacteria, and coriobacteria were significantly correlated with TMA production in the mixed fermentation system but did not produce notable quantities of TMA from TMAO in pure culture.
    - TMAO stimulated the growth of Enterobacteriaceae; these bacteria produced most TMA from TMAO.
    - Reduction of TMAO by the gut microbiota (predominantly Enterobacteriaceae) to TMA followed by host uptake of TMA into the bloodstream from the intestine and its conversion back to TMAO by host hepatic enzymes is an example of metabolic retroconversion. TMAO influences microbial metabolism depending on isolation source and taxon of gut bacterium.
  • [1.10
    - Depletion of Bacteroides xylanisolvens, Odoribacter splanchnicus, Eubacterium eligens, Roseburia inulinivorans, and Roseburia intestinalis.
    - At the functional level, healthy metagenomes were both enriched in pathways of starch degradation V, glycolysis III (from glucose), CDP‐diacylglycerol biosynthesis, and folate transformations.
    - R inulinivorans and R intestinalis are major contributors to starch degradation V.
    - E eligens greatly contribute to the pathway CDP‐diacylglycerol biosynthesis.
    - B xylanisolvens and B uniformis contribute to folate transformations II.
    - Two gut microbial metabolites, nicotinic acid and hydrocinnamic acid, had significantly higher predicted abundance in the control samples compared to the patients in the Chinese cohort, and interestinglynicotinic acid is already an effective lipid‐lowering drug to reducing cardiovascular risk.
  • [1.11
    - The gut microbiota composition of patients with atherosclerosis (AS) contains relatively high levels of Collinsella.


[Coverage other Diseases (Overlap > 0.25)]

DiseaseOverlapCommon increased OrganismCommon decreased Organism
Atherosclerosis 1.0000 18 (100%) : Anaeroglobus | Atopobium parvulum | Bulleidia moorei | Collinsella | Curvibacter | Cytomegalovirus | EBV | Eggerthella lenta | Enterobacter aerogenes | Enterobacteriaceae | Escherichia coli | Fusobacterium nucleatum | HSV-1 | Klebsiella | Lactobacillus salivarius | Mucor racemosus | Ruminococcus gnavus | Streptococcus 11 (100%) : Alistipes shahii | Bacteroides | Bacteroides xylanisolvens | Eubacterium | Eubacterium eligens | Faecalibacterium prausnitzii | Odoribacter splanchnicus | Prevotella copri | Roseburia | Roseburia intestinalis | Roseburia inulinivorans
Colorectal cancer 0.5227 9 (50%) : Atopobium parvulum | Bulleidia moorei | Collinsella | Cytomegalovirus | Enterobacteriaceae | Escherichia coli | Fusobacterium nucleatum | Klebsiella | Streptococcus 6 (55%) : Bacteroides | Eubacterium | Eubacterium eligens | Faecalibacterium prausnitzii | Prevotella copri | Roseburia
Crohn's disease 0.4672 7 (39%) : Collinsella | Enterobacteriaceae | Escherichia coli | Fusobacterium nucleatum | Klebsiella | Ruminococcus gnavus | Streptococcus 6 (55%) : Bacteroides | Eubacterium | Faecalibacterium prausnitzii | Roseburia | Roseburia intestinalis | Roseburia inulinivorans
Cystic fibrosis 0.4293 4 (22%) : Enterobacteriaceae | Escherichia coli | Ruminococcus gnavus | Streptococcus 7 (64%) : Bacteroides | Bacteroides xylanisolvens | Eubacterium eligens | Faecalibacterium prausnitzii | Roseburia | Roseburia intestinalis | Roseburia inulinivorans
Type 2 diabetes 0.4217 7 (39%) : Eggerthella lenta | Escherichia coli | Fusobacterium nucleatum | Klebsiella | Lactobacillus salivarius | Ruminococcus gnavus | Streptococcus 5 (45%) : Eubacterium | Faecalibacterium prausnitzii | Prevotella copri | Roseburia intestinalis | Roseburia inulinivorans
Ulcerative Colitis 0.4116 5 (28%) : Enterobacteriaceae | Escherichia coli | Fusobacterium nucleatum | Ruminococcus gnavus | Streptococcus 6 (55%) : Alistipes shahii | Bacteroides | Eubacterium | Faecalibacterium prausnitzii | Odoribacter splanchnicus | Roseburia
Cirrhosis 0.3939 6 (33%) : Enterobacteriaceae | Escherichia coli | Klebsiella | Lactobacillus salivarius | Ruminococcus gnavus | Streptococcus 5 (45%) : Bacteroides | Eubacterium eligens | Faecalibacterium prausnitzii | Odoribacter splanchnicus | Roseburia intestinalis
Autism 0.3662 5 (28%) : Collinsella | Eggerthella lenta | Enterobacteriaceae | Ruminococcus gnavus | Streptococcus 5 (45%) : Bacteroides | Eubacterium eligens | Faecalibacterium prausnitzii | Roseburia | Roseburia intestinalis
Obesity 0.3561 3 (17%) : Bulleidia moorei | Collinsella | Fusobacterium nucleatum 6 (55%) : Bacteroides | Bacteroides xylanisolvens | Eubacterium | Faecalibacterium prausnitzii | Odoribacter splanchnicus | Roseburia
Multiple Sclerosis 0.3384 4 (22%) : Collinsella | EBV | Eggerthella lenta | Streptococcus 5 (45%) : Bacteroides | Bacteroides xylanisolvens | Faecalibacterium prausnitzii | Prevotella copri | Roseburia
Parkinson's Disease 0.3207 5 (28%) : Eggerthella lenta | Enterobacteriaceae | Klebsiella | Lactobacillus salivarius | Streptococcus 4 (36%) : Faecalibacterium prausnitzii | Prevotella copri | Roseburia | Roseburia intestinalis
Irritable bowel syndrome 0.3030 6 (33%) : Collinsella | Enterobacteriaceae | Escherichia coli | Klebsiella | Ruminococcus gnavus | Streptococcus 3 (27%) : Bacteroides | Eubacterium | Roseburia
Chronic kidney disease 0.2753 5 (28%) : Enterobacteriaceae | Escherichia coli | Lactobacillus salivarius | Ruminococcus gnavus | Streptococcus 3 (27%) : Bacteroides | Faecalibacterium prausnitzii | Roseburia
Pulmonary tubercolosis 0.2652 3 (17%) : Collinsella | Escherichia coli | Streptococcus 4 (36%) : Eubacterium eligens | Roseburia | Roseburia intestinalis | Roseburia inulinivorans
Primary sclerosing cholangitis-IBD 0.2652 3 (17%) : Collinsella | Lactobacillus salivarius | Streptococcus 4 (36%) : Bacteroides | Faecalibacterium prausnitzii | Prevotella copri | Roseburia

[Coverage Factors (Overlap > 0.10)]

FactorOverlapCommon increased OrganismCommon decreased Organism
Chemotherapy treatment 0.1364 0 (0%) 3 (27%) : Bacteroides | Faecalibacterium prausnitzii | Roseburia

Common References